News

Apply for the 5th Annual Crab Trap

You thought the Shark Tank was tough…wait until you enter the the BioHealth Capital Region Crab Trap!

Submit your application for the opportunity to be named the company with the most commercial potential at the 2020 BioHealth Regional Forum, $10,000, and MORE!

Application Deadline: March, 20th 2020

Finalists will be announced: April 3rd, 2020

Finalist Presentations BioHealth Capital Region Forum Event: April 15th, 2020

 

Click here to apply

Recent News

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and

09/14/2026

BRAINBox Solutions Announces Agreement with Prolight Diagnostics for Commercial Supply of Pyros® Devices for Delivery of BRAINBox Concussion Diagnostics/Prognostics at Point-of-Care

BRAINBox Solutions announced it has entered into an agreement with Prolight Diagnostics to supply its Psyros® instruments and cartridges for use in point-of-care (PoC) delivery of BRAINBox’s TBI diagnostic/prognostic tests for concussion (also known as mTBI or Acute Traumatic Encephalopathy). “This agreement is an important step towards commercialization of our solutions and reflects the successful